|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00549679 |
This study will evaluate the safety and tolerability of the PDE4 inhibitor for the first time in mild to moderate COPD patients.
Condition | Intervention | Phase |
Chronic Obstructive Pulmonary Disease (COPD) |
Drug: GSK256066 |
Phase II |
MedlinePlus related topics: | COPD (Chronic Obstructive Pulmonary Disease) |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Safety Study |
Official Title: | A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients |
Estimated Enrollment: | 105 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | September 2008 |
Estimated Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 40 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Subjects who require treatment with any of the following from the start of the run-in period (Day -14) until the end of the treatment phase:
Contact: US GSK Clinical Trials Call Center | 877-379-3718 |
Estonia | |||||
GSK Investigational Site | Recruiting | ||||
Tallinn, Estonia, 13419 | |||||
Finland | |||||
GSK Investigational Site | Recruiting | ||||
Tampere, Finland, 33520 | |||||
Germany | |||||
GSK Investigational Site | Completed | ||||
Berlin, Germany, 10717 | |||||
GSK Investigational Site | Withdrawn | ||||
Berlin, Germany, 14050 | |||||
GSK Investigational Site | Recruiting | ||||
Hamburg, Germany, 22291 | |||||
Germany, Bayern | |||||
GSK Investigational Site | Recruiting | ||||
Gauting, Bayern, Germany, 82131 | |||||
Netherlands | |||||
GSK Investigational Site | Withdrawn | ||||
Hengelo, Netherlands, 7555 DL | |||||
GSK Investigational Site | Not yet recruiting | ||||
EINDHOVEN, Netherlands, 5623 EJ | |||||
GSK Investigational Site | Recruiting | ||||
VELDHOVEN, Netherlands, 5504 DB | |||||
GSK Investigational Site | Completed | ||||
HOORN, Netherlands, 1624 NP | |||||
GSK Investigational Site | Completed | ||||
HORN, Netherlands, 6085 NM | |||||
New Zealand | |||||
GSK Investigational Site | Withdrawn | ||||
Wellington 6004, New Zealand, 6004 | |||||
Russian Federation | |||||
GSK Investigational Site | Recruiting | ||||
St. Petersburg, Russian Federation, 197022 | |||||
GSK Investigational Site | Recruiting | ||||
Yaroslavl, Russian Federation, 150003 | |||||
GSK Investigational Site | Recruiting | ||||
Moscow, Russian Federation, 105 077 | |||||
GSK Investigational Site | Recruiting | ||||
Barnaul, Russian Federation, 656 045 | |||||
Slovakia | |||||
GSK Investigational Site | Recruiting | ||||
Martin, Slovakia, 036 59 | |||||
GSK Investigational Site | Active, not recruiting | ||||
Bratislava, Slovakia, 826 06 | |||||
GSK Investigational Site | Active, not recruiting | ||||
Kosice, Slovakia, 041 90 | |||||
United Kingdom, Lancashire | |||||
GSK Investigational Site | Not yet recruiting | ||||
Manchester, Lancashire, United Kingdom, M23 9LT |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MD MDsc FFPM | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | IPC101939 |
First Received: | October 24, 2007 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00549679 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|